Introduction
Breast cancer is the most common cause of cancer among women and the second leading cause of cancer deaths in Western countries. The metastatic spread of tumor cells from their primary site to distant organs in the body is the principal cause of mortality [
1]. Thus, understanding metastasis is one of the most significant problems in cancer research [
2‐
4]. A key challenge is to develop suitable animal models to enhance our understanding of the mechanisms that underlie metastatic progression and to evaluate treatments for metastatic diseases [
5].
Currently available in vivo models of breast tumor progression and metastasis include transplantable models and genetically engineered mice that develop primary and metastatic cancers [
5‐
8]. Transplantable tumor models include syngeneic models, in which the cancer cell line/transplanted tissue is of the same genetic background as the animal, and xenograft models whereby human cancer cell lines or tissues are transplanted into immunocompromised hosts, such as nude and severe combined immunodeficient mice [
5]. Breast xenograft tumors are produced by injecting breast cancer cells into the flank (subcutaneous) or preferably into the mammary fat pad (orthotopic) of a female animal. Subcutaneous xenograft mouse models are typically the standard for cancer drug screening in the pharmaceutical industry [
9], but the use of orthotopic xenotransplantation models should be favored since tissue specific stromal cell interactions play a crucial role in the biology of cancer progression and metastasis.
Metastasis is a consequence of multiple steps, including growth of a primary tumor, intravasation, arrest and growth in a secondary site [
2,
3]. The study of metastasis requires both a relevant mouse model and an appropriate tumor cell line. On the basis of gene profiling and previous in vivo results, rat mammary adenocarcinoma MTLn3 cells have been identified as a suitable model to study breast cancer progression and treatment [
10,
11]. The epidermal growth factor receptor (EGFR, also referred as ErbB1) is often overexpressed in breast cancer, resulting not only in uncontrolled cell proliferation [
12,
13] but also in increased tumor cell motility and invasion [
14‐
16]. To study intravasation leading to metastasis formation, we therefore evaluated the effect of enhanced ErbB1 signaling in MTLn3 cells in the orthotopic Rag mouse breast cancer model.
Efficient metastasis formation is dependent on tumor cell autonomous biological programs that define migration, intravasation survival and extravasation [
14]. For xenotransplantation models, immune cell responses to foreign antigens on the injected tumor cells need to be avoided, necessitating the use immunocompromised hosts.
The most widely used immunodeficient mice (nude and SCID) lack the adaptive immune response. However, these mice still harbor large numbers of cells of the innate immune system, including natural killer (NK) cells [
17]. These cells are important in the killing of viable circulating tumor cells that, through enhanced invasion and intravasation programs, have efficiently escape the primary tumor and have the potential to form metastasis [
18‐
25]. Indeed, we showed previously that the MTLn3 cells are killed by the circulating NK-cells in Fischer 344 rats, thus preventing efficient lung metastasis formation. Although pretreatment with NK-depleting antibodies allowed experimental lung metastasis formation in this model [
26,
27], continuous NK depleting antibody injection is an undesirable requirement for a breast/tumor metastasis model. To study breast tumor progression and metastasis formation using MTLn3 cells expressing the EGF receptor, an appropriate animal model with a compromised innate and adaptive immune system was still required.
The goal of the current study was to develop an MTLn3 cell breast tumor metastasis animal model that allows the unbiased analysis of tumor cell-dependent metastasis programs, independent of adaptive and innate immune system surveillance. We first show that increased expression of the ErbB1 receptor in MTLn3 cells was required for lung metastasis formation in Rag2−/− γc−/− mice. Secondly, by comparing different immune deficient mouse models, we confirm that Rag2−/− γc−/− mice, which lack NK cells, are an ideal recipient animal model for MTLn3 and 4T1 cells to study the metastasis process. In conclusion, we have established an improved animal model that can be used to study the biological steps that are essential in the formation of distant metastasis.
Materials and methods
Cell lines
MTLn3 rat mammary adenocarcinoma cells [
28] were cultured as previously described [
29]. MTLn3-GFP-ErbB1 and MTLn3-GFP cell-lines were previously described [
16] and were maintained in αMEM (Life Technologies, Inc., Gaithersburg, MD) supplemented with 5% fetal bovine serum (Life Technologies). The mouse mammary metastatic 4T1-luc cell-line was purchased from Caliper Lifescience and cultured in RPMI-1640 supplemented with 10% fetal bovine serum (Life Technologies).
Reagents
Mouse anti-human ErbB1 was purchased from Calbiochem (EMD Biosciences, San Diego, California). Rabbit anti-human ErbB1 used for immunoblotting was purchased from Cell Signaling Technology (Danvers, MA). Goat anti-mouse APC was purchased from Cedarlane (Ontario, Canada). Alpha modified minimal essential medium (a-MEM), Fetal Bovine Serum (FBS), phosphate buffered saline (PBS) and trypsin were from Life Technologies (Rockville, MD, USA).
ErbB1 staining
Flow cytometry
MTLn3 were harvested and incubated for 45 min with 50 μl of mAb ErbB1 (2 μg/ml in PBS). Cells were washed with cold PBS and incubated for 45 min with the secondary antibody goat-anti mouse APC in PBS (2 μg/ml). Finally, cells were washed and suspended in 0.3 ml PBS. ErbB1 and GFP expression were analysed by flow cytometry (FACScalibur, Becton Dickinson).
Immunoblotting
Cells were scraped in ice-cold TSE (10 nM Tris–HCl, 250 mM sucrose, 1 mM EGTA, pH 7.4) supplemented with inhibitors. After sonication of either cells or tissue, protein concentrations were determined by the Bio-Rad (Hercules, CA) protein assay using IgG as a standard. Equal amounts of total cellular protein were separated by 7.5% SDS–PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA). Blots were blocked with 5% (w/v) bovine serum albumin in TBST [0.5 mol/l NaCl, 20 mmol/l Tris–HCl, 0.05% (v/v) Tween 20 (pH 7.4)] and probed with primary antibody (overnight, 4°C) followed by incubation with secondary horseradish peroxidase–coupled antibody and visualized with Enhanced Chemiluminescence Plus reagent (Amersham Biosciences, Uppsala, Sweden) by scanning on a multilabel Typhoon imager 9400 (Amersham Biosciences).
Animals
Female BALB/c nu/nu, SCID [CB17/lcr-Prkdcscid/Crl] and SCID Beige [CB17/lcr.Cg-Prkdcscid Lystbg/Crl] mice aged between 6 and 7 weeks were purchased from Charles River (L’Arbresle, France). BALB/c mice aged between 6 and 7 weeks were purchased from Janvier (Uden, The Netherlands). 6-week old Rag2−/− γc−/− mice were obtained from in house breeding. Animals were housed in individually ventilated cages under sterile conditions containing three mice per cage. Sterilised food and water were provided ad libitum.
Spontaneous and experimental metastasis assays
To measure spontaneous metastasis, tumor cells were grown to 70–85% confluence before being harvested for cell counting. Cells (5 × 105 for the MTLn3 or 1 × 105 for the 4T1-luc) were injected into the right thoracic mammary fat pads of the different mouse strains. Cells were injected in a volume of 100 μl of PBS without Ca2+ and Mg2+ through a 25-gauge needle. Tumor growth rate was monitored at weekly intervals after inoculation of tumor cells. Horizontal (h) and vertical (v) diameters were determined, and tumor volume (V) was calculated (V = 4/3π(1/2[√(h × v)]3). After 3 or 4 weeks, the animals were anesthetized with pentobarbital and the lungs were excised and rinsed in ice-cold PBS. For the GFP-labeled MTLn3 cell-lines, the right lung was used to count the tumor burden. For rough estimation, the right lungs were imaged with the Fluorescent imaging unit IVIS (see below). And for detailed quantification, the flat side of the right lung was analysed with the immunofluorescence microscope. With a ×10 objective lens, we screened the flat surface of the lobe and counted the number of GFP positive metastases. Subsequently, the right lung was fixed in 4% paraformaldehyde. The left lung was injected with ink solution, de-stained in water and fixed in Fekete’s (4.3% (v/v) acetic acid, 0.35% (v/v) formaldehyde in 70% ethanol). For the 4T1-luc cell-line, the lung tumor burden was quantified by counting the number of surface metastases which were represented by white spots on the ink-injected left lung.
For the experimental lung metastasis assay, 2 × 105 MTLn3 cells were injected into the lateral tail veins of 5- to 7-week-old female Rag2−/− γc−/− mice. Three to four weeks after injection, the mice were euthanized, and the lungs were removed and subjected to fluorescent imaging and histologic examination as described below.
Fluorescent imaging
Fluorescent imaging (FLI) was performed with a high sensitivity, cooled CCD camera mounted in a light-tight specimen box (IVIS™; Xenogen). Imaging and quantification of signals were controlled by the acquisition and analysis software Living Image® (Xenogen). For ex vivo imaging, lungs were excised, placed into a petri dish, and imaged for 1–2 min. Tissues were subsequently fixed as above and prepared for standard histopathology evaluation.
Measurement of tumor cell blood burden
At the end point of the MTLn3 spontaneous metastasis assay, mice were sacrificed with Nembutal. The right side of the thoracic cavity was exposed by a simple skin flap surgery. Blood was taken from the right atrium via heart puncture with a 25-gauge needle and 1-ml syringe coated with heparin. Blood (0.2–1.0 ml) was harvested from each animal. The blood was immediately plated into 100-mm-diameter dishes filled with 5% fetal bovine serum/αMEM growth medium. The next day, the plates were rinsed with fresh medium containing 0.8 mg/ml geneticin to selectively grow the tumor cells. After 3–7 days, all dishes were scanned for GFP expression with a Typhoon imager 9400 (Amersham Biosciences). The tumor cell clones were counted by image analysis of the obtained scans. Tumor blood burden was calculated as total colonies in the dish divided by the volume of blood taken.
Tumor histology and quantitative assessment of the efficiency of metastasis
The primary tumors and lungs from each mouse were used for histological analysis. Samples were fixed in formalin and embedded in paraffin, and 5-μm sections were stained with H&E.
Statistical analysis
Student’s t test was used to determine if there was a significant difference between two means (P < 0.05). Values are presented as mean ± SD. Significant differences are marked in the graphs.
Discussion
Modeling metastasis in vivo is challenging but necessary for studying the mechanisms underlying the tumor cell biological processes (e.g. cell migration) that enable certain cells to spread to other parts of the body [
7]. EGFR-signaling is a pathway that is known to be involved in breast tumor progression. We examined whether EGFR overexpression in MTLn3 cells results in increased number of lung metastases in the Rag2
−/− γc
−/− mice. In contrast of previous findings [
12,
13,
16], our data indicate that increased expression of ErbB1 in the MTLn3 mammary adenocarcinoma cells results in slower primary tumor growth. In vitro, MTLn3-GFP-ErbB1 cells show an increased proliferation rate compared with control cells, suggesting instead that there may be a difference in cell survival. Indeed, MTLn3-GFP-ErbB1 cells are less able to tolerate culture at high density compared to MTLn3-GFP control cells. MTLn3-GFP-ErbB1 cells may be less tolerant of the fat pad injection procedure resulting in fewer surviving cells that can develop into a primary tumor.
ErbB1 overexpression enhances the ability to intravasate and, thus, provide sufficient seeding capacity to allow lung metastasis formation in the Rag2
−/− γc
−/− mice. Indeed, there were an increased number of tumor cells in the circulation of mice with ErbB1-expressing tumors, while few cells could be detected in the blood collected from control tumor bearing mice. Furthermore, the efficiency of lung colonization by MTLn3 cells (experimental metastasis assay) was independent of ErbB1 overexpression. These results are consistent with previous in vivo studies showing that ErbB1 expression can enhance invasiveness—most probably through increased chemotaxis to gradients of EGF [
33,
34]. The angiogenesis marker, CD31, failed to reveal differences in blood vessel density through the primary tumor of both groups (data not shown). The presence of macrophages in the Rag2
−/− γc
−/− mice allows the paracrine loop with tumor cells to take place and thus enhances invasiveness in response to EGF.
In this study, we have shown that the presence of remaining innate immune cells, including NK cells, in the nude and SCID mouse does not affect the growth of the primary tumor but inhibits the formation of lung metastases [
6,
17,
27,
38]. Indeed, we have found that the Rag2
−/− γc
−/− mouse which lacks NK cells is an excellent recipient animal model to study breast tumor formation and progression when using MTLn3 overexpressing ErbB1 cells or 4T1 cells. Previous reports demonstrated the contribution of NK cells in tumor growth and metastasis [
27,
39‐
42]. In particular, Dewan et al. [
43] demonstrated the direct role of NK cells in tumor growth and metastasis using NOD/SCID/γc
null (NOG) mice lacking T, B and NK cells which are similar to the Rag2
−/− γc
−/− mice used in our study. They showed both increased efficiency of engraftment (subcutaneous inoculation only) and spontaneous metastasis of the human breast cancer cell-line MB-MDA-231 in the NOG mice compared to the SCID mice demonstrating the critical role of NK cells in tumor growth and metastasis [
44]. In our study, we used the rat mammary adenocarcinoma MTLn3 cell-line overexpressing ErbB1. Although we did not observe a significant role for NK cells in engraftment and primary tumor growth, they did appear to be important for the formation of spontaneous lung metastases. Since the Rag2
−/− γc
−/− and NOG mice have similar immunodeficiencies, i.e. T, B, and NK cell reductions, similar results for the NOG and Rag2
−/− γc
−/− mouse were to be expected. Zhang et al. [
45] also conclude that Rag2
−/− γc
−/− mice, similar to NOD/SCID/γc
null (NOG) mice, provide a suitable immunodeficient setting for human engraftment. Nevertheless, our results concerning efficient engraftment of the tumor cells do not show that NK cells play a role in this tumor progression step. Tumor growth in the SCID Beige mice was slightly delayed although these also lack NK cells. In fact, the beige mutation not only results in loss of cytotoxic T cells and selective impairment of NK cell functions but also in macrophage defects which could explain the lower average tumor weight and most probably the reduced number of lung metastases [
35,
36]. Indeed, it has been shown that macrophages can form a paracrine loop with tumor cells to enhance invasiveness in response to EGF stimulation [
33,
34,
46,
47]. Reduced macrophage activity in SCID Beige mice could therefore explain why tumor growth and the number of lung metastases were reduced compared to Rag mice.
To further confirm that the Rag mouse is a suitable animal model for studying breast cancer progression, we injected two human xenografts models MDA-MB-231-luc [
48] and a bone metastastic variant BO2-MDA-MB-231-luc [
49] cell-lines. These MDA-MB-231 cell lines poorly grew after orthotopic transplantation in Rag mice (data not shown). Typically, these cell lines are used in intracardial injection studies for bone metastasis model. The parental MB-MDA-231 cells do grow orthopically to 1 cm in diameter typically in 30–35 days after inoculation of 1 × 10
6 cells in SCID mice. After removal of the mammary fat pad tumors, mice are then sacrificed 4–5 weeks later and few spontaneous metastases can be detected [
50]. Although not tested, we anticipate that the parental MB-MDA-231 cells would form orthotopic breast tumors in Rag2
−/− γc
−/− mice, but the necessary removal of the primary tumor for further metastases development as well as the ultimate number of lung metastasis formed, does not fit our requirements for an easy and reliable breast cancer/metastasis animal model. In addition to our MTLn3 cell line, we also tested the 4T1 mouse mammary tumor cell-line, which is known to be one of the only few breast cancer models with the capacity to metastasize efficiently to sites affected in human breast cancer [
51]. When introduced orthotopically in the syngeneic Balb/c mouse model which possesses an intact immune system, 4T1 should be capable of metastasising to several organs typically affected in breast cancer [
12,
13]. However, when we injected the 4T1-luc cells in the Rag2
−/− γc
−/− and Balb/c mice, we could only detect lung metastases in the Rag2
−/− γc
−/− mice although a primary tumor formed in both mouse strains. Even after 3 weeks of experiment the primary tumor started to shrink in the Balb/c mice which has been described as a biphasic growth related to immune system function [
37]. Indeed, Tao et al. observed a regression in weeks 2 through 4 in normal BALB/c mice which was associated with necrosis and infiltration of leukocytes. Biphasic tumor growth did not occur in athymic nude or SCID BALB/c mice suggesting involvement of an acquired immune response in the effect. We also injected the 4T1-luc in Balb/c mice purchased from different suppliers (data not shown). The results were similar: very few lung metastases detectable. In conclusion, our results suggest that NK cells play an important role in inhibiting metastasis formation but not in tumor growth.
In summary, ErbB1 overexpression in the MTln3 cells delayed the primary tumor growth but was essential for efficient intravasation and lung metastasis formation. This suggests a role for ErbB1 expression in tumor cells to drive the biological processes that are essential in intravasation, such as cell motility. Secondly, we provide evidence for the crucial role of NK cells in metastasis formation but not in tumor growth. Metastasis formation is a key determinant of poor prognosis for breast cancer patients; enhancing NK activity is therefore a potential immunotherapeutic strategy for combatting this detrimental step.
The Rag2−/− γc−/− mouse model, in combination with MTLn3-ErbB1 and 4T1 tumor cells, is a clinically relevant model for the study of breast cancer cell growth and metastasis. The 4T1 syngeneic metastatic breast cancer model may be useful to validate potential gene targets and processes implicated in cell migration and intravasation.